AstraZeneca to Sell Astra Tech Business to Dentsply International Inc.

By LMT Communications, Inc.

Posted Jun 30, 2011 in Industry News

January 2012--


On June 22, AstraZeneca announced that it has agreed to sell its Astra Tech business to Dentsply for approximately $1.8 billion in cash.


Astra Tech, headquartered in Mölndal, Sweden, has two main business divisions: a dental division, which is engaged in the research, development, manufacturing and marketing of dental implants, and a healthcare division, a business focused on medical devices for use primarily in urology and surgery. In 2010, Astra Tech recorded worldwide revenue of $535 million and normalised EBITDA of $105 million, with net assets valued at approximately $0.3 billion at May 2011 rates of exchange.


The transaction is anticipated to be completed during the second half of 2011, subject to receipt of relevant regulatory clearances. Upon closing, a gain will be recorded as "other operating income" in the AstraZeneca profit and loss account. The gain will be considered a "significant item" to be excluded from Core financial measures. As...

Please Log In or Sign Up (it's free) to read the rest of this article
About The Author

  • LMT Communications, Inc.

    LMT Communications delivers the business strategies, information, dental laboratory news and education that dental laboratory decision-makers need to succeed. In Print. In Person. Online.

Please Log In or Sign Up to post to this article